SCHEMBL2457313

SCHEMBL2457313

CCOC(C)Oc1[c]cccc1

nearest known ligand 0.38

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.33
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2457205 0.92 LMNA (0.34) LMNAL3MBTL1
SCHEMBL8022241 0.86
SCHEMBL8665980 0.83 LTA4H (0.34) L3MBTL1
SCHEMBL8335291 0.81 TSHR (0.35) LMNAL3MBTL1
SCHEMBL11704312 0.81 ALDH1A1 (0.32)
SCHEMBL483028 0.81 KDM4E (0.30)
SCHEMBL4912418 0.81 L3MBTL1 (0.32) L3MBTL1
SCHEMBL8678808 0.78 L3MBTL1 (0.33) LMNAL3MBTL1
SCHEMBL440263 0.78 MCHR1 (0.34)
SCHEMBL4891090 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US claimed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US claimed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP claimed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO claimed
US-5847218-A Sulfonium salts and chemically amplified positive resist compositions SHIN-ETSU CHEMICAL CO., LTD. (JP) 1998-12-08 US claimed
CN-114292204-B Preparation method of dihydro oat alkaloid 重庆美杉蓝科技发展有限公司 2024-01-30 CN disclosed
US-10845703-B2 Film-forming composition containing silicone having crosslinking reactivity NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2020-11-24 US disclosed
CN-107075302-B Film-forming composition containing crosslinking reactive silicon 日产化学工业株式会社 2020-08-04 CN disclosed
US-20180335698-A1 FILM-FORMING COMPOSITION CONTAINING SILICONE HAVING CROSSLINKING REACTIVITY NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2018-11-22 US disclosed
EP-3222688-A1 FILM-FORMING COMPOSITION CONTAINING CROSSLINKABLE REACTIVE SILICONE Nissan Chemical Industries, Ltd. (JP) 2017-09-27 EP disclosed
US-8497334-B2 Conjugated diene polymer, conjugated diene polymer composition, and method for producing conjugated diene polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-07-30 US disclosed
US-20110245407-A1 CONJUGATED DIENE POLYMER, CONJUGATED DIENE POLYMER COMPOSITION, AND METHOD FOR PRODUCING CONJUGATED DIENE POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-10-06 US disclosed
EP-0782164-B1 Plasma display filter MITSUI CHEMICALS INC (JP) 2002-04-10 EP disclosed
US-6337423-B1 BIND TO VOLTAGE-GATED SODIUM ION CHANNELS TO MODULATE ACTIVITY ADVANCED MEDICINE, INC. 2002-01-08 US disclosed
US-6274289-B1 Chemical resist thickness reduction process ADVANCED MICRO DEVICES, INC. 2001-08-14 US disclosed
US-6030746-A CHEMICALLY AMPLIFIED POSITIVE RESIST COMPRISES A ORGANIC SOLVENT, AN ALKALI SOLUBLE RESIN, A PHOTOACID GENERATOR AND A DISSOLUTION RATE REGULATOR SHIN-ETSU CHEMICAL CO., LTD. (JP) 2000-02-29 US disclosed
US-5856561-A Bisphenol carboxylic acid tertiary ester derivatives and chemically amplified positive resist compositions SHIN-ETSU CHEMICAL CO., LTD. (JP) 1999-01-05 US disclosed
US-5847218-A Sulfonium salts and chemically amplified positive resist compositions SHIN-ETSU CHEMICAL CO., LTD. (JP) 1998-12-08 US disclosed
US-5804102-A USE OF METAL COMPLEXES TO CUT OFF NEAR INFRARED RAYS; PREVENTION OF INTERFERENCE BETWEEN TELEVISION AND OTHER REMOTE CONTROLLED ELECTRONICS MITSUI CHEMICALS, INC. (JP) 1998-09-08 US disclosed
EP-0782164-A1 Plasma display filter MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1997-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 LMNA 3296/4885L3MBTL1 1959/4885THRB 1128/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 LMNA 3477/4885L3MBTL1 2007/4885THRB 1015/4885
US-10845703-B2 Film-forming composition containing silicone having crosslinking reactivity SETDB1, KDM2B, SRSF9 LMNA 217/4885L3MBTL1 1020/4885THRB 2510/4885
US-20180335698-A1 FILM-FORMING COMPOSITION CONTAINING SILICONE HAVING CROSSLINKING REACTIVITY SETDB1, KDM2B, CD79B LMNA 252/4885L3MBTL1 756/4885THRB 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.